<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01123824</url>
  </required_header>
  <id_info>
    <org_study_id>PKD11147</org_study_id>
    <secondary_id>2009-010105-37</secondary_id>
    <nct_id>NCT01123824</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic and Pharmacokinetic Study of 2 Different Dose Regimen of Clopidogrel in CYP2C19 Genotyped Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Double-dummy, Two Period, Two Treatment Cross-over Pharmacodynamic and Pharmacokinetic Study of Clopidogrel Given as 5-day Repeated Oral Doses (300 mg Loading Dose Followed by 75 mg/Day and 600 mg Loading Dose Followed by 150 mg/Day) in 4 Different Groups of CYP2C19 Genotyped Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

        -  Investigate the possible role of the CYP2C19 genotype in Adenosine diphosphate
           (ADP)-induced platelet aggregation after administration of a standard dose regimen of
           clopidogrel (300 mg loading dose followed by 75 mg/day for 4 days) in healthy male and
           female subjects

      Secondary Objectives:

        -  Assess the pharmacodynamic activity of a higher dose regimen of clopidogrel (600 mg
           loading dose followed by 150 mg/day for 4 days)

        -  Compare the pharmacokinetic profiles of clopidogrel active metabolite between the
           selected groups of genotyped subjects and the 2 dose regimen
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration per subject is 10-12 weeks broken down as follows:

        -  Screening: 2 to 40 days before the first dosing

        -  Period 1: 7 days including 5 days treatment

        -  Washout: At least 14 days after the last dosing

        -  Period 2: 7 days including 5 days treatment

        -  End of study: 7 to 10 days after the last dosing
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum platelet aggregation intensity (MAI) induced by Adenosine diphosphate (ADP) 5 µM after 5 days treatment</measure>
    <time_frame>Day 5 of each period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum platelet aggregation intensity (MAI) induced by ADP 20 µM after 5 days treatment</measure>
    <time_frame>Day 5 of each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet reactivity index -Vasodilator-stimulated phosphoprotein test (PRI-VASP) after 5 days treatment</measure>
    <time_frame>Day 5 of each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clopidogrel active metabolite pharmacokinetic parameters (Cmax, tmax, AUC0-24, AUClast) after 5 days treatment</measure>
    <time_frame>Up to 24 hours postdose on Day 5 for each period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sequence clopidogrel 300/75 mg - 600/150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1:
Day 1: clopidogrel, 300 mg loading dose + placebo
Day 2 to Day 5: clopidogrel, 75 mg + placebo, once daily
Period 2:
Day 1: clopidogrel, 600 mg loading dose
Day 2 to Day 5: clopidogrel, 150 mg, once daily
Each intake is at around 8:00 AM fasted for at least 10 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence clopidogrel 600/150 mg - 300/75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1:
Day 1: clopidogrel, 600 mg loading dose
Day 2 to Day 5: clopidogrel, 150 mg, once daily
Period 2:
Day 1: clopidogrel, 300 mg loading dose + placebo
Day 2 to Day 5: clopidogrel, 75 mg + placebo, once daily
Each intake is at around 8:00 AM fasted for at least 10 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CLOPIDOGREL</intervention_name>
    <description>Pharmaceutical form: tablets
Route of administration: oral</description>
    <arm_group_label>Sequence clopidogrel 300/75 mg - 600/150 mg</arm_group_label>
    <arm_group_label>Sequence clopidogrel 600/150 mg - 300/75 mg</arm_group_label>
    <other_name>SR25990</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Pharmaceutical form: matching tablets
Route of administration: oral</description>
    <arm_group_label>Sequence clopidogrel 300/75 mg - 600/150 mg</arm_group_label>
    <arm_group_label>Sequence clopidogrel 600/150 mg - 300/75 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Healthy subject in good health, as determined by a medical history, physical examination
        including vital signs and clinical laboratory tests:

          -  with a body weight between 45 kg and 95 kg if male, between 40 kg and 85 kg if female,
             and with a Body Mass Index (BMI) between 18 and 30 kg/m²

          -  classified into one of the 4 groups of metabolizers according to his/her CYP2C19
             genotype:

               -  Ultrarapid Metabolizers (UMs, CYP2C19*1/*17 and CYP2C19*17/*17)

               -  homozygous Extensive Metabolizers (homoEMs, CYP2C19*1/*1)

               -  heterozygous Extensive Metabolizers (heteroEMs, CYP2C19*1/*2 and CYP2C19*1/*3)

               -  Poor Metabolizers (PMs, CYP2C19*2/*2 and CYP2C19*2/*3)

        Exclusion criteria:

          -  Evidence of inherited disorder of coagulation/hemostasis functions

          -  Subject smoking more than 10 cigarettes or equivalent per day

          -  Unability to abstain from intake of any drug affecting hemostasis throughout the whole
             study duration

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>International Clinical Development Study Director</last_name>
    <role>Study Chair</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Simon T, Bhatt DL, Bergougnan L, Farenc C, Pearson K, Perrin L, Vicaut E, Lacreta F, Hurbin F, Dubar M. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects. Clin Pharmacol Ther. 2011 Aug;90(2):287-95. doi: 10.1038/clpt.2011.127. Epub 2011 Jun 29.</citation>
    <PMID>21716274</PMID>
  </results_reference>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2010</study_first_submitted>
  <study_first_submitted_qc>May 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2010</study_first_posted>
  <last_update_submitted>December 14, 2011</last_update_submitted>
  <last_update_submitted_qc>December 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

